
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc demonstrated robust financial performance in its recent quarter, with a gross margin of 27.1% for 4Q24, marking a year-over-year increase of 50 basis points and exceeding expectations. The company's revenue from biopharma testing and services surged by 59%, reaching $51 million in 2024 compared to $32 million in 2023, driven by an improved customer mix and increased clinical test volumes. Furthermore, substantial growth in MRD testing revenue and successful collaborations with partners like Tempus indicate strong market demand and a favorable outlook for future operations.
Bears say
Personalis Inc experienced a significant decline in quarterly revenues, with 4Q24 revenue reported at $16.8 million, representing a 15% year-over-year decrease, which is well below earlier estimates. The company's operating expenses also fell but reflect ongoing financial challenges, highlighting slower than expected growth in both its biopharma and clinical diagnostics segments. Additionally, the steep drop in VA MVP revenue from $4.4 million in 3Q24 to $0.2 million in 4Q24 points to serious risks, including lower customer adoption rates and increasing competition, potentially undermining future revenue projections.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares